Skip to content
 

Chief Executive's Statement

2011 was Reckitt Benckiser’s 12th consecutive year of high quality growth, and another year in which RB beat its targets.

  • Total net revenue grew +13%1 to £9,485m – ahead of the +12% target.
  • Excellent growth in emerging markets and Powerbrands Dettol, Nurofen, Mucinex, Strepsils, Gaviscon and Harpic.
  • Like-for-like growth, excluding acquisitions, of +4%1.
  • Recently acquired SSL grew net revenue by +6%1 to £843m like-for-like.
  • Suboxone film captured a 48% volume share of the US market.
  • Adjusted net income grew +11%1 to £1,818m – ahead of the +10% target.
  • Strong cash flow took net debt down to £1,795m.
Rakesh KapoorIn 2012 we are targeting total Company net revenue growth excluding RB Pharmaceuticals of 200 basis points (bps) above our market growth rate. We expect the market to grow at 1-2%. 2012 will be a year of higher investment, but we still aim to maintain our operating margins2.

Rakesh Kapoor
Chief Executive

1 At constant exchange rates
2 Excluding RB Pharmaceuticals

Financial highlights of 2011

£9485m Our net revenue in 2011. £2487m Adjusted operating profit in 2011. 125.0p Divident per share

* Includes final 2011 dividend of 70p recommended by the Board

Read more

  • Lysol
  • Mucinex
  • Frenchs
  • Airwick
  • Nurofen
  • Vanish
  • Durex
  • Clearasil
  • Dettol
  • Cillet Bang
  • Strepsils
  • Scholl
  • Gaviscon
  • Mortein
  • Woolite
  • Veet
  • harpic
  • Calgon
  • Finish

This site uses cookies. By continuing to browse the site without disabling them, you consent to our use of cookies. To learn more about the types of cookies we use, please view our cookie policy.

Continue using the site